plant
molecular
farm
offer
costeffect
scalabl
approach
express
recombin
protein
propos
altern
convent
product
platform
develop
countri
recent
year
numer
proof
concept
establish
plant
produc
biolog
activ
recombin
protein
immunolog
relev
vaccin
antigen
compar
made
convent
express
system
drive
mani
advanc
remark
plastic
plant
proteom
enabl
extens
engin
host
cell
well
develop
improv
express
vector
facilit
higher
level
protein
product
date
plantderiv
viral
glycoprotein
test
human
influenza
haemagglutinin
express
mgkg
howev
mani
viral
glycoprotein
potenti
vaccin
immunogen
accumul
low
level
planta
critic
consider
product
mani
protein
heterolog
express
system
complex
posttransl
modif
control
fold
glycosyl
disulphid
bridg
requir
reproduc
nativ
glycoprotein
structur
review
address
potenti
shortcom
plant
express
system
discuss
strategi
optim
exploit
technolog
product
immunolog
relev
structur
authent
glycoprotein
use
vaccin
immunogen
develop
plantbas
express
system
scalabl
econom
product
recombin
protein
constitut
major
paradigm
shift
manufactur
pharmaceut
technolog
fast
becom
establish
sever
nich
area
tradit
manufactur
approach
fall
shortsuch
rapid
respons
requir
product
scalabl
limit
rybicki
stoger
et
al
streatfield
et
al
major
drive
forc
molecular
farm
lower
cost
involv
product
biomass
less
stringent
infrastructur
requir
typic
ferment
system
edgu
et
al
rybicki
tschofen
et
al
uniqu
featur
particularli
appeal
develop
countri
typic
suffer
greater
burden
infecti
diseas
infrastructur
tradit
pharmaceut
product
often
larg
complet
absent
hefferon
et
al
rybicki
et
al
addit
plant
safer
tradit
express
system
produc
endotoxin
support
growth
potenti
infecti
virus
prion
moustafa
et
al
plant
also
mediat
complex
posttransl
modif
includ
glycosyl
disulphid
bond
format
fay
et
al
tschofen
et
al
furthermor
remark
plastic
plant
proteom
enabl
simultan
coexpress
multipl
protein
enabl
care
regul
manipul
secretori
pathway
product
protein
homogen
mammalianlik
glycosyl
castilho
steinkelln
castilho
et
al
lastli
plantderiv
vaccin
antigen
offer
potenti
oral
immun
although
expect
degre
formul
would
necessari
least
ensur
dose
consist
rybicki
immun
unargu
effect
biomed
intervent
infecti
diseas
result
success
licens
vaccin
use
human
nabel
consist
biomark
vaccin
efficaci
induct
neutral
antibodi
case
mani
envelop
virus
target
glycoprotein
spike
surfac
nabel
given
observ
develop
glycoproteinbas
antigen
major
focal
point
develop
vaccin
mani
viral
pathogen
summar
figur
hajj
hussein
et
al
although
focu
review
also
noteworthi
addit
use
vaccin
antigen
recombin
glycoprotein
also
repres
potenti
diagnost
reagent
particularli
one
health
initi
rybicki
whilst
recombin
viral
structur
protein
gener
accumul
reason
level
plant
mani
viral
glycoprotein
express
poorli
even
threshold
detect
standard
method
reason
complet
understood
report
number
differ
viral
glycoprotein
like
observ
other
work
publish
experi
associ
sever
tissu
necrosi
indic
endoplasm
reticulum
er
stress
aris
accumul
misfold
protein
associ
unfold
protein
respons
howel
pera
et
al
phoolcharoen
et
al
phenomenon
describ
literatur
extracellular
subunit
ebola
glycoprotein
rotaviru
pera
et
al
phoolcharoen
et
al
observ
laboratori
fulllength
gngc
protein
rift
valley
fever
viru
crimeancongo
haemorrhag
fever
viru
well
premembran
envelop
protein
zika
viru
worth
note
howev
tissu
necrosi
limit
viral
glycoprotein
may
aris
overexpress
protein
exce
fold
capac
system
liu
howel
although
minimum
express
yield
total
solubl
protein
gener
regard
prerequisit
justifi
industri
product
rare
achiev
especi
viral
glycoprotein
rybicki
howev
mani
influenza
haemagglutinin
ha
glycoprotein
express
unusu
high
level
planta
candid
vaccin
antigen
report
accumul
mgkg
daoust
et
al
shoji
et
al
amongst
impress
demonstr
plant
molecular
farm
pioneer
work
medicago
inc
develop
highli
scalabl
express
platform
product
influenza
viru
glycoprotein
lead
vaccin
candid
plantderiv
influenza
viru
haemagglutinin
ha
viruslik
particl
current
evalu
phase
efficaci
trial
success
lead
fda
approv
time
write
influenza
ha
remain
viral
glycoprotein
express
plant
evalu
human
trial
pillet
et
al
unclear
mani
viral
glycoprotein
accumul
low
level
planta
although
surmis
may
due
either
incompat
endogen
plant
chaperon
inadequ
level
crucial
chaperon
requir
facilit
fold
overexpress
protein
lack
adequ
level
molecular
chaperon
acknowledg
bottleneck
heterolog
express
system
hsu
betenbaugh
rudolph
lili
taken
true
plant
major
challeng
need
address
identif
chaperon
even
combin
chaperon
ratelimit
express
given
glycoprotein
review
discuss
recent
success
product
plantproduc
viral
glycoprotein
critic
discuss
consider
product
authent
vaccinerelev
mimet
nativ
glycoprotein
plant
figur
product
recombin
glycoprotein
subunit
vaccin
protect
viral
infect
virusderiv
glycoprotein
often
repres
major
antigen
determin
viral
infect
therefor
product
recombin
glycoprotein
heterolog
express
system
consider
interest
vaccin
develop
diagram
show
typic
envelop
virion
surfac
decor
trimer
glycoprotein
facilit
entri
suscept
target
cell
glycoprotein
gene
clone
heterolog
express
vector
protein
overexpress
exampl
transient
agrobacteriummedi
infiltr
glycoprotein
purifi
contamin
host
protein
formul
immun
elicit
neutral
antibodi
viru
mani
case
yield
low
gener
suffici
larg
batch
vaccin
programm
howev
number
differ
strategi
taken
consider
may
improv
yield
could
also
improv
function
antigen
includ
factor
target
protein
secretori
pathway
nglycosyl
proteolyt
matur
along
secretori
pathway
influenc
chaperon
endoplasm
reticulum
eukaryot
transloc
glycoprotein
er
essenti
impart
authent
glycosyl
posttransl
modif
ptm
well
impos
qualiti
control
prior
progress
along
secretori
pathway
er
newli
synthes
protein
interact
molecular
chaperon
glycosyl
enzym
act
concert
facilit
fold
matur
protein
braakman
hebert
termin
misfold
protein
incomplet
assembl
polypeptid
progress
beyond
er
instead
target
erassoci
protein
degrad
erad
pathway
proteosom
degrad
hiller
et
al
jensen
et
al
lippincottschwartz
et
al
sommer
jentsch
ward
et
al
given
critic
role
secretori
pathway
facilit
proper
fold
glycosyl
target
recombin
protein
differ
subcellular
local
may
improv
accumul
expens
nativ
structur
glycoprotein
natur
encod
ntermin
signal
sequenc
typic
amino
acid
residu
target
newli
synthes
protein
er
hegd
bernstein
natur
signal
peptid
determin
effici
transloc
er
subsequ
cleavag
leader
peptid
glycoprotein
braakman
hebert
illustr
point
report
mammalian
cell
nativ
hiv
env
signal
peptid
ineffici
cleav
result
prolong
retent
protein
er
contamin
virion
aberrantli
fold
env
speci
crook
et
al
land
et
al
li
et
al
li
et
al
use
highli
effici
foreign
signal
peptid
often
exploit
product
glycoprotein
heterolog
system
honeybe
melittin
signal
sequenc
insect
cell
tissu
plasminogen
activ
leader
sequenc
mammalian
express
system
tessier
et
al
sever
exampl
heterolog
signal
peptid
use
glycoprotein
express
plant
list
tabl
routin
make
use
lph
leader
sequenc
murin
monoclon
antibodyderiv
signal
peptid
target
recombin
protein
plant
secretori
pathway
approach
shown
promis
product
trimer
env
glycoprotein
hiv
solubl
gn
antigen
rvfv
mbewana
anoth
commonli
use
signal
peptid
protein
disulphid
isomeras
pdi
signal
sequenc
use
medicago
inc
product
recombin
influenza
ha
ha
express
control
nativ
signal
peptid
daoust
et
al
contrast
fraunhof
usa
report
use
pathogenesisrel
protein
prp
signal
peptid
produc
solubl
influenza
ha
plant
shoji
et
al
found
solubl
rvfv
gn
glycoprotein
express
fuse
lph
signal
sequenc
pdi
signal
sequenc
mbewana
pertin
exampl
includ
rabi
viru
glycoprotein
produc
transgen
tomato
use
nativ
signal
peptid
transgen
nicotiana
tabacum
control
prp
signal
peptid
ashraf
et
al
mcgarvey
et
al
latter
antigen
modifi
contain
ctermin
er
retent
signal
protect
mice
lethal
rabi
challeng
ashraf
et
al
appear
impact
differ
signal
peptid
heterolog
protein
express
determin
empir
illustr
point
report
detect
express
truncat
hiv
antigen
could
achiev
tobacco
plant
use
barley
alphaamylas
signal
peptid
signal
sequenc
appl
pectinas
n
plumbaginifolia
calreticulin
rice
alphaamylas
use
kessan
et
al
recent
studi
suggest
tissu
necrosi
heterolog
protein
express
planta
could
link
improp
cleavag
signal
peptid
author
report
substitut
arabidopsi
thaliana
chitinas
signal
peptid
nativ
signal
sequenc
transform
growth
result
high
level
protein
product
whilst
still
maintain
healthi
phenotyp
n
benthamiana
plant
wilber
et
al
also
worth
note
target
recombin
ha
protein
plant
secretori
pathway
result
format
envelop
vlp
bud
plasma
membran
absenc
accessori
protein
daoust
et
al
phenomenon
appear
uniqu
plant
heterolog
express
system
requir
neuraminidas
sever
sialic
acid
linkag
tether
bud
virion
host
cell
chen
et
al
plant
howev
lack
endogen
sialic
acid
activ
enabl
hacontain
particl
bud
plasma
membran
apoplast
space
plant
leav
daoust
et
al
seveno
et
al
group
also
observ
assembl
similar
envelop
ha
vlp
rybicki
although
earli
attempt
recov
recombin
protein
includ
use
preclud
recoveri
envelop
vlp
mortim
et
al
similar
phenomenon
describ
fraunhof
usa
product
envelop
ebola
viru
vlp
evlp
compos
fulllength
glycoprotein
karczewski
ysibov
use
way
improv
immunogen
small
solubl
protein
may
otherwis
poorli
immunogen
bachmann
jen
zabel
et
al
whilst
abil
plant
mediat
nglycosyl
regard
advantag
primit
prokaryot
express
system
complex
glycan
deriv
plant
uniqu
contain
core
b
xylos
fucos
lack
b
galactos
sialic
acid
characterist
mammalian
cell
glycosyl
figur
observ
glycoepitop
immunogen
small
anim
report
serum
antibodi
epitop
found
human
rais
concern
possibl
allerg
reaction
rapid
clearanc
follow
administr
bardor
et
al
bosch
schot
jin
et
al
spite
trepid
medicago
habas
vaccin
candid
report
safe
even
volunt
preexist
plant
allergi
suggest
concern
larg
unwarr
howev
acknowledg
transient
antibodi
respons
plantderiv
glycoepitop
observ
although
gener
weak
potenti
neg
implic
use
protein
plantspecif
glycoepitop
prompt
extens
effort
human
glycosyl
protein
plant
elimin
plantspecif
glycan
introduct
human
glycosyltransferas
review
strasser
et
al
also
interest
note
number
differ
plant
polysaccharid
even
explor
adjuv
sever
advanc
clinic
trial
review
rosalesmendoza
et
al
hiv
env
glycoprotein
amongst
heavili
glycosyl
protein
describ
approxim
half
molecular
mass
attribut
glycan
joyc
et
al
laski
et
al
glycan
hostderiv
consid
selfantigen
enabl
viru
mask
vulner
epitop
poorli
immunogen
shield
julien
et
al
mcguir
et
al
sok
et
al
wei
et
al
similarli
influenza
ha
also
contain
multipl
glycosyl
site
appear
increas
sinc
presum
enabl
viru
escap
neutral
antibodi
herv
et
al
job
et
al
skehel
et
al
wei
et
al
despit
report
glycan
occup
may
lower
plantproduc
protein
product
platform
medicago
plantproduc
ha
report
contain
glycan
six
potenti
nglycan
site
extracellular
portion
protein
le
mauff
et
al
ward
et
al
unclear
potenti
underglycosyl
impact
recombin
hiv
env
glycoprotein
express
plant
expect
glycan
trimer
cao
et
al
underglycosyl
could
potenti
compromis
fold
glycoprotein
nglycan
critic
recruit
lectin
chaperon
calnexin
calreticulin
wada
et
al
furthermor
case
env
mani
broadli
neutral
antibodi
isol
natur
infect
target
epitop
contain
glycan
compon
suggest
recombin
immunogen
reproduc
structur
crispin
et
al
encouragingli
recent
public
castilho
colleagu
suggest
coexpress
leishmania
major
oligosaccaryltransferas
use
improv
glycan
occup
plantderiv
protein
castilho
et
al
furthermor
ongo
effort
human
glycosyl
recombin
plantproduc
protein
demonstr
success
remov
plantspecif
nglycan
moieti
introduct
human
glycosyltransferas
planta
strasser
et
al
although
approach
develop
primarili
product
recombin
antibodi
expect
rang
plantproduc
viral
glycoprotein
expand
similar
approach
implement
kallolimath
steinkelln
particularli
interest
aspect
work
determin
impact
antigen
immunogen
plantproduc
viral
glycoprotein
express
wildtyp
glycoengin
plant
hiv
env
glycoprotein
appear
uniqu
mani
epitop
target
broadli
neutral
antibodi
virus
isol
natur
infect
incorpor
glycan
compon
andrabi
et
al
ballajhagjhoorsingh
et
al
blattner
et
al
gorman
et
al
julien
et
al
kong
et
al
lyumki
et
al
sander
et
al
scanlan
et
al
sok
et
al
trkola
et
al
encouragingli
recombin
hiv
env
produc
rosenberg
colleagu
n
benthamiana
report
react
sever
prototyp
monoclon
antibodi
includ
specif
target
glycandepend
epitop
outer
domain
glycoprotein
rosenberg
et
al
glycoprofil
purifi
hiv
env
protein
reveal
predominantli
highmannosetyp
glycan
contain
plantspecif
fucos
b
xylos
residu
rosenberg
et
al
natur
infect
virionassoci
env
compris
predominantli
unprocess
oligomannos
moieti
bonomelli
et
al
door
et
al
consid
import
hallmark
nativ
structur
steric
constraint
trimer
limit
access
glycan
process
enzym
along
secretori
pathway
bonomelli
et
al
door
et
al
pritchard
et
al
whilst
encourag
plantproduc
hiv
env
antigen
reproduc
structur
complex
glycandepend
epitop
recent
studi
suggest
sialic
acid
residu
may
contribut
epitop
target
broadli
neutral
antibodi
andrabi
et
al
given
observ
wildtyp
plant
may
ideal
product
authent
mimet
glycoprotein
sialyl
natur
occur
plant
seveno
et
al
recent
studi
report
artifici
engin
sialic
acid
biosynthet
pathway
plant
could
use
address
potenti
limit
castilho
et
al
castilho
et
al
kallolimath
et
al
paccalet
et
al
appar
contradict
studi
conduct
kong
et
al
compar
influenc
express
systemdepend
glycosyl
conclud
cell
lack
sialic
acid
may
improv
immunogen
recombin
hiv
env
immunogen
though
necessarili
neutral
antibodi
respons
mani
glycoprotein
requir
proteolyt
cleavag
assum
matur
fusionentri
conform
requir
infect
therefor
abil
heterolog
express
system
mediat
authent
process
protein
import
consider
hiv
env
glycoprotein
exampl
undergo
proteolyt
cleavag
furin
subtilisinlik
proteas
transloc
along
secretori
pathway
decroli
et
al
gu
et
al
hallenberg
et
al
vollenweid
et
al
proteolyt
matur
glycoprotein
necessari
assum
correct
quaternari
structur
ring
et
al
import
implic
vaccin
design
cleavagedefect
env
trimer
report
assum
aberr
conform
induc
antibodi
epitop
steric
inaccess
context
function
virionbound
trimer
therefor
unabl
neutral
viru
ring
et
al
tran
et
al
given
observ
trimer
hiv
env
immunogen
often
produc
mammalian
cell
cultur
replac
nativ
cleavag
site
hexaarginin
motif
coexpress
heterolog
furin
promot
optim
cleavag
recombin
glycoprotein
binley
et
al
furin
activ
natur
occur
along
plant
secretori
pathway
although
preced
exist
coexpress
proteas
produc
function
human
transform
growth
factor
planta
suggest
theoret
may
possibl
produc
cleav
hiv
env
glycoprotein
plant
wilber
et
al
anoth
potenti
complic
product
proteolyt
cleav
glycoprotein
labil
associ
respect
subunit
case
cleav
hiv
env
trimer
artifici
disulphid
bond
typic
introduc
interfac
ectodomain
ensur
two
subunit
remain
associ
cleavag
binley
et
al
natur
infect
absenc
stabil
mutat
subunit
subunit
may
shed
leav
stump
surfac
virion
propos
serv
immunolog
decoy
moor
et
al
accordingli
import
hiv
envderiv
vaccin
antigen
stabl
compon
remain
associ
maximum
immunogen
recent
studi
mammalian
cell
cultur
manag
circumv
requir
furin
cleavag
employ
flexibl
glycinerich
linker
place
nativ
hiv
env
cleavag
site
georgiev
et
al
sharma
et
al
cleavageindepend
trimer
report
authent
mimic
virionbound
trimer
retain
nativelik
antigen
elicit
neutral
antibodi
preclin
studi
georgiev
et
al
pauthner
et
al
sharma
et
al
similar
approach
also
report
product
respiratori
syncyti
viru
fusion
glycoprotein
mammalian
cell
furin
cleavag
site
replac
flexibl
linker
suggest
strategi
may
broadli
applic
viral
type
glycoprotein
ebolaviru
gp
joyc
et
al
exploit
design
strategi
produc
solubl
cleavageindepend
env
trimer
plant
facilit
first
immunogen
studi
trimer
plantproduc
env
protein
margolin
et
al
submit
public
structur
analog
influenza
viru
ha
glycoprotein
also
requir
proteolyt
cleavag
viral
infect
result
structur
rearrang
expos
fusion
peptid
bullough
et
al
owen
compan
cleavag
h
immatur
precursor
glycoprotein
mediat
ubiquit
cellular
proteas
includ
endoproteas
furin
may
even
mediat
proteas
coinfect
bacteria
galloway
et
al
steinhauer
stienekegrob
et
al
express
ha
plant
howev
report
yield
singl
product
kda
consist
size
expect
uncleav
ha
daoust
et
al
mortim
et
al
shoji
et
al
subsequ
report
confirm
presenc
low
level
ha
ha
extracellular
transmembran
subunit
ha
respect
suggest
level
precursor
cleavag
occur
albeit
ineffici
le
mauff
et
al
unlik
hiv
cleavag
requir
elicit
protect
immun
influenza
glycoprotein
uncleav
ha
vlp
confer
protect
lethal
challeng
daoust
et
al
mett
et
al
pillet
et
al
shoji
et
al
endoplasm
reticulum
eukaryot
major
site
protein
fold
qualiti
control
nascent
protein
interact
molecular
chaperon
saibil
protein
fold
er
direct
two
major
chaperon
system
classic
chaperon
system
carbohydratebind
system
although
two
system
mutual
exclus
braakman
hebert
fold
glycoprotein
intrins
link
nglycosyl
recent
review
richard
strasser
strasser
trim
glycan
moieti
signal
entri
exit
calnexincalreticulin
qualiti
control
cycl
lannoo
van
damm
misfold
glycoprotein
retain
er
cycl
calnexincalreticulin
fold
cycl
correct
conform
achiev
target
degrad
figur
absenc
proper
glycosyl
nascent
glycoprotein
may
prone
misfold
result
mispair
cystein
residu
best
illustr
work
daniel
colleagu
provid
evid
strateg
placement
glycan
influenza
ha
serv
shield
suscept
cystein
residu
fold
daniel
et
al
calnexin
calreticulin
form
complex
oxidoreductas
catalys
format
disulphid
bond
frickel
et
al
oliv
et
al
oliv
et
al
zapun
et
al
addit
member
protein
disulphid
isomeras
famili
also
respons
catalys
disulphid
bond
result
level
builtin
redund
system
rutkevich
et
al
given
extend
period
diverg
evolut
mammal
plant
low
express
level
report
mani
viral
glycoprotein
may
due
incompat
endogen
plant
chaperon
machineri
support
put
homologu
key
chaperon
known
interact
glycoprotein
exhibit
lowlevel
sequenc
ident
human
counterpart
current
explor
coexpress
human
molecular
chaperon
planta
patent
applic
improv
product
heterolog
glycoprotein
base
hypothesi
endogen
plant
chaperon
may
repres
critic
bottleneck
high
level
express
coexpress
variou
protein
disulphid
isomeras
may
improv
disulphid
bond
format
solubl
hiv
env
antigen
produc
plant
subunit
hiv
env
contain
nine
intrachain
disulphid
bond
addit
disulphid
bond
present
transmembran
subunit
go
et
al
leonard
et
al
given
presenc
cystein
residu
subunit
obviou
potenti
aberr
disulphid
bond
format
report
crosslink
dimer
aggreg
literatur
unsurpris
leonard
et
al
owen
compan
other
report
presenc
unresolv
higher
molecular
weight
product
follow
western
blot
plantproduc
hiv
env
protein
rosenberg
et
al
margolin
et
al
submit
public
rosenberg
colleagu
specul
compris
higher
order
oligom
incomplet
resolv
sdspage
rosenberg
et
al
hypothes
unresolv
higher
molecular
weight
product
actual
aggreg
misfold
protein
scrambl
disulphid
bridg
observ
higher
molecular
weight
product
dissoci
presenc
deterg
vari
condit
ph
salt
concentr
howev
boil
recombin
protein
extend
length
time
presenc
bmercaptoethanol
result
improv
dissoci
higher
order
molecular
weight
protein
speci
suggest
improv
disulphid
bond
format
may
improv
protein
product
number
viral
glycoprotein
vaccin
candid
success
express
plant
date
either
transient
gener
transgen
transplastom
plant
tabl
includ
antigen
highimpact
human
diseas
influenza
hiv
well
vectorborn
zoonot
viral
diseas
zika
dengu
west
nile
fever
japanes
enceph
coronaviru
infect
crimeancongo
haemorrhag
rift
valley
fever
rabi
infecti
bronchiti
newcastl
diseas
ebola
mani
test
specif
immunogen
anim
includ
infecti
bronchiti
influenza
newcastl
diseas
carbohydratemedi
fold
endoplasm
reticulum
follow
translat
nascent
protein
red
enter
endoplasm
reticulum
er
translocon
pore
sequenti
interact
network
chaperon
enzym
acquir
correct
higher
order
structur
entri
er
oligosaccharyltransferas
complex
ost
transfer
preform
glc
man
nac
glycan
precursor
asn
asnxserthr
motif
polypeptid
chain
two
outermost
glucos
residu
sequenti
remov
glucosidas
gi
glucosidas
ii
gii
signal
entri
result
monoglucosyl
glcman
nac
protein
calnexin
cnx
calreticulin
crt
fold
cycl
calnexin
membranebound
homologu
calreticulin
preferenti
interact
nascent
protein
associ
er
membran
calreticulin
indic
diagram
sake
simplic
interact
cnxcrt
facilit
coordin
activ
chaperon
oxidoreductas
assist
fold
incorrectli
fold
protein
reglucosyl
udpglucos
glycoprotein
glucosyltransferas
uggt
signal
reentri
cnxcrt
fold
cycl
undergo
anoth
round
chaperonemedi
fold
contrast
correctli
fold
protein
act
gii
result
remov
remain
glucos
residu
signal
releas
cnxcrt
pathway
enabl
export
protein
golgi
glycoprotein
may
undergo
sever
round
chaperonemedi
fold
assum
correct
quaternari
structur
continu
along
secretori
pathway
contrast
termin
misfold
glycoprotein
target
proteolyt
degrad
via
endoplasm
reticulinassoci
degrad
erad
pathway
rabi
test
efficaci
use
anim
challeng
model
encourag
result
human
season
influenza
diseas
present
caus
three
influenza
viru
subtyp
two
influenza
viru
b
subtyp
yamagata
victoria
annual
adult
children
infect
million
case
sever
ill
death
although
figur
recent
increas
death
base
new
model
studi
iuliano
et
al
convent
chicken
eggbas
vaccin
technolog
product
capac
billion
dose
trival
vaccin
product
level
million
dose
howev
take
month
make
produc
vaccin
thu
vaccin
antigen
chosen
base
virus
circul
time
northern
hemispher
influenza
season
predict
caus
problem
due
vaccin
mismatch
circul
type
dugan
potenti
rapid
respons
scalabl
plantbas
express
best
illustr
pioneer
work
medicago
inc
fraunhof
usa
group
develop
candid
vaccin
pandem
influenza
strain
daoust
et
al
shoji
et
al
stoger
et
al
streatfield
et
al
given
slow
product
time
limit
product
capac
use
embryon
hen
egg
tradit
influenza
vaccin
manufactur
equip
respond
timeous
suffici
volum
pandem
outbreak
daoust
et
al
quan
et
al
typic
eggbas
product
split
virion
vaccin
take
month
due
limit
inher
product
platform
hamper
variabl
product
yield
manini
et
al
contrast
medicago
inc
usa
report
product
fulli
formul
ha
vlp
vaccin
within
day
releas
sequenc
pandem
strain
daoust
et
al
furthermor
product
platform
rapidli
scalabl
use
success
produc
million
dose
monoval
vlp
vaccin
within
day
defens
advanc
research
project
agenc
darpa
blue
angel
programm
http
wwwrtcom
fraunhof
centr
molecular
biotechnolog
usa
describ
develop
similar
transient
plant
express
platform
product
solubl
ha
antigen
report
yield
purifi
vaccin
month
shoji
et
al
platform
highli
flexibl
use
produc
ha
sever
season
pandem
influenza
subtyp
daoust
et
al
mett
et
al
pillet
et
al
shoji
et
al
shoji
et
al
shoji
et
al
b
shoji
et
al
antigen
demonstr
promis
immunogen
preclin
anim
model
sever
report
protect
lethal
viru
challeng
aoust
et
al
mett
et
al
pillet
et
al
shoji
et
al
shoji
et
al
shoji
et
al
b
consist
studi
clinic
trial
report
vaccin
safe
highli
immunogen
human
volunt
chichest
et
al
cum
et
al
landri
et
al
landri
et
al
ward
et
al
prompt
limit
access
vaccin
south
africa
pandem
group
develop
similar
product
platform
express
fulllength
solubl
ha
antigen
mortim
et
al
human
immunodefici
viru
respons
unpreced
global
pandem
particularli
subsaharan
africa
bear
disproportion
burden
global
infect
rel
size
shao
williamson
broadli
protect
vaccin
urgent
need
combat
spread
hiv
even
partial
effect
vaccin
expect
make
larg
impact
epidem
medlock
et
al
current
stateoftheart
subunit
vaccin
base
ration
engin
solubl
env
trimer
mimet
produc
mammalian
cell
cultur
system
intent
elicit
neutral
antibodi
sander
moor
high
cost
limit
product
capac
avail
expect
particularli
problemat
consid
likelihood
repeat
immun
requir
shao
williamson
given
structur
similar
influenza
ha
hiv
env
glycoprotein
reason
assum
plant
may
capac
emul
structur
hiv
env
glycoprotein
trimer
karlsson
hedestam
et
al
prompt
us
explor
potenti
n
benthamiana
product
transient
agroinfect
trimer
env
glycoprotein
base
hiv
subtyp
circul
subsaharan
africa
patent
applic
ppa
uk
margolin
et
al
submit
public
studi
report
success
express
signific
portion
hiv
env
glycoprotein
plant
first
publish
studi
describ
express
major
hiv
env
glycoprotein
rosenberg
colleagu
produc
solubl
protein
protein
lack
transmembran
cytoplasm
domain
n
benthamiana
reagent
evalu
reactiv
plantproduc
monoclon
antibodi
rosenberg
et
al
author
report
recombin
env
protein
produc
mgkg
transient
stabl
transgen
express
rosenberg
et
al
preced
patent
file
medicago
inc
describ
product
chimer
viruslik
particl
compris
synthet
consensu
group
env
protein
fuse
transmembran
cytoplasm
domain
influenza
ha
patent
applic
report
express
nativ
hiv
env
protein
could
detect
intern
patent
applic
number
wo
antigen
produc
studi
modifi
remov
cleavag
site
known
result
aberr
structur
unless
flexibl
linker
peptid
introduc
interfac
retain
conform
mobil
two
subunit
georgiev
et
al
ring
et
al
sharma
et
al
also
noteworthi
major
surfac
glycoprotein
simian
immunodefici
viru
siv
success
produc
transgen
corn
aim
develop
oral
immunogen
vaccin
although
immunogen
report
horn
et
al
recent
describ
develop
platform
express
solubl
env
trimer
n
benthamiana
plant
patent
applic
ppa
uk
antigen
exploit
residu
glycinerich
linker
peptid
interfac
subunit
elimin
requir
furinmedi
cleavag
natur
occur
plant
wilber
et
al
preliminari
immunogen
studi
confirm
protein
immunogen
rabbit
howev
despit
elicit
high
titr
bind
antibodi
vaccin
induc
low
level
neutral
antibodi
remov
size
exclus
chromatographi
nontrimer
env
speci
improv
induct
neutral
antibodi
improv
anim
prime
recombin
modifi
vaccinia
ankara
mva
viru
express
gag
env
antigen
knowledg
first
studi
report
immunogen
plantproduc
env
trimer
anim
model
margolin
et
al
submit
public
flavivirus
west
nile
wnv
zika
zikv
yellow
fever
yfv
japanes
enceph
jev
dengu
denv
compris
group
specif
mosquitoborn
virus
within
famili
flaviririda
recent
emerg
reemerg
wnv
yfv
zikv
america
zumla
et
al
wnv
tickborn
enceph
europ
kaaijk
luytj
result
renew
interest
develop
prophylact
vaccin
pathogen
concern
compound
find
infect
zikv
pregnanc
associ
birth
defect
recent
outbreak
brazil
yakob
walker
similar
limit
term
scalabl
product
cost
convent
product
platform
influenza
vaccin
driven
interest
potenti
molecular
farm
produc
vaccin
emerg
flavirus
cardonaospina
et
al
et
al
yap
smith
sever
dengu
envelop
antigen
produc
plant
although
pauciti
immunogen
data
support
util
vaccin
immunogen
kim
et
al
kim
et
al
martinez
et
al
saejung
et
al
domain
iii
flaviviru
env
glycoprotein
target
neutral
antibodi
natur
infect
therefor
import
target
vaccinemedi
protect
beasley
barrett
crill
roehrig
zhao
et
al
mart
colleagu
report
success
product
truncat
envelop
protein
chimer
fusion
hepat
b
core
antigen
dengu
viru
envelop
domain
iii
ediii
potenti
use
vaccin
diagnost
reagent
martinez
et
al
dengu
ediii
also
produc
fusion
protein
vibrio
cholera
toxin
b
subunit
transgen
potatoespresum
use
oral
vaccin
although
immunogen
report
kim
et
al
similarli
ediii
express
solubl
protein
transgen
tobacco
rice
callu
dengu
viru
glycoprotein
also
produc
modifi
polyprotein
transplastom
lettuc
contain
part
capsid
addit
premembran
env
protein
kanagaraj
et
al
spite
lack
immunogen
report
mani
studi
immun
mice
n
benthamianaderiv
dengu
ediii
shown
elicit
neutral
antibodi
mice
warrant
develop
antigen
saejung
et
al
similarli
transient
express
west
nile
viru
ediii
antigen
report
immunogen
mice
et
al
chimer
bamboo
mosaic
viru
particl
present
ediii
japanes
enceph
viru
also
produc
plant
shown
elicit
neutral
antibodi
mice
chen
et
al
recent
increas
demand
report
advers
effect
current
live
attenu
yfv
vaccin
prompt
develop
plantproduc
subunit
vaccin
altern
tottey
et
al
tottey
colleagu
success
produc
envelop
glycoprotein
solubl
protein
chimer
fusion
bacteri
lichenas
protect
mice
lethal
challeng
note
howev
compar
less
immunogen
live
attenu
vaccin
tottey
et
al
mani
solubl
vaccin
candid
would
benefit
multimer
form
synthet
nanoparticl
improv
immunogen
larg
size
nanoparticl
facilit
entri
lymphat
enabl
drainag
lymph
node
interact
profession
antigenpres
cell
manolova
et
al
addit
repeat
array
antigen
promot
crosslink
b
cell
result
sustain
durabl
antibodi
respons
even
absenc
tcell
stimul
bachmann
jen
zabel
et
al
motiv
recent
outbreak
america
two
studi
arizona
state
univers
describ
product
zika
viru
glycoprotein
antigen
plant
first
success
express
solubl
e
protein
retain
nativ
antigen
base
bind
panel
monoclon
antibodi
elicit
cellular
humor
respons
immun
mice
furthermor
level
neutral
antibodi
immun
anim
exceed
threshold
requir
protect
immun
yang
et
al
group
also
develop
vlp
vaccin
compris
hepat
b
core
antigen
present
zika
viru
e
protein
domain
iii
circumv
potenti
induc
antibodydepend
enhanc
ade
infect
dengu
infect
yang
et
al
sever
vectorborn
zoonot
diseas
recent
identifi
prime
candid
develop
vaccin
diagnost
one
health
initi
notabl
exampl
bunyavirus
crimeancongo
haemorrhag
fever
rift
valley
fever
virus
rybicki
mani
pathogen
affect
livestock
caus
zoonot
infect
direct
contact
human
also
worth
note
less
stringent
regulatori
requir
commerci
veterinari
vaccin
make
compar
quicker
road
market
human
vaccinesand
success
anim
vaccin
could
quickli
becom
human
vaccin
virus
rybicki
end
solubl
rvfv
gn
glycoprotein
express
low
level
stabli
transform
arabidopsi
thaliana
although
recombin
protein
could
detect
western
blot
mrna
express
confirm
rtpcr
fresh
plant
materi
report
oral
immunogen
mice
kalbina
et
al
group
express
purifi
chimer
particleform
gn
antigen
n
benthamiana
plant
contain
transmembran
cytoplasm
domain
influenza
ha
mbewana
vaccin
candid
particular
interest
immun
gn
suffici
confer
protect
immun
de
boer
et
al
fulllength
crimeancongo
haemorrhag
fever
viru
gngc
protein
also
success
produc
tobacco
leav
hairi
root
cultur
mice
fed
transgen
materi
igg
iga
antibodi
elicit
although
express
level
viral
protein
low
ghiasi
et
al
anoth
plantproduc
viral
glycoprotein
potenti
vaccin
antigen
rabi
viru
glycoprotein
g
express
transgen
maiz
tobacco
tomato
ashraf
et
al
lozarubio
et
al
mcgarvey
et
al
transgen
maiz
express
g
protein
shown
protect
sheep
virul
challeng
although
level
protect
lower
commerci
vaccin
glycoprotein
also
produc
transgen
potato
tuber
extract
suffici
protect
chicken
virul
challeng
follow
oral
intramuscular
immun
zhou
et
al
similarli
oral
immunogen
newcastl
diseas
viru
fusion
protein
produc
transgen
maiz
report
protect
chicken
challeng
guerreroandrad
et
al
extracellular
subunit
ebola
viru
glycoprotein
express
tobacco
plant
immun
complex
human
monoclon
antibodi
phoolcharoen
et
al
interestingli
author
report
could
produc
suffici
quantiti
without
heavi
chain
fusion
due
extens
leaf
necrosi
hypothes
presenc
monoclon
antibodi
segment
enabl
improv
recruit
molecular
chaperon
suggest
plant
chaperon
machineri
may
repres
critic
bottleneck
glycoprotein
express
compon
fusion
protein
properli
fold
base
reactiv
conform
monoclon
antibodi
author
report
subcutan
immun
mice
immun
complex
elicit
immun
respons
compar
protect
venezuelan
equin
enceph
viru
vaccin
although
antibodi
titr
admittedli
lower
truncat
form
sar
coronaviru
spike
glycoprotein
express
transplastom
stabl
nuclear
transform
tobacco
lettuc
leav
use
oral
vaccin
li
et
al
molecular
farm
cusp
accept
mainstream
technolog
product
heterolog
pharmaceut
particular
appeal
resourcelimit
region
recent
year
born
wit
licensur
first
plantmad
pharmaceut
use
humanstaligluceras
alphawith
sever
present
advanc
clinic
trial
plantmad
pharmaceut
proven
highli
scalabl
safe
human
despit
unfound
concern
regard
impact
plantspecif
glycosyl
limit
express
yield
address
improv
express
vector
enabl
high
level
express
mani
pharmaceut
relev
protein
although
histor
glycoprotein
difficult
produc
planta
number
differ
viral
glycoprotein
success
express
plant
includ
notabl
influenza
ha
hiv
env
sever
glycoprotein
emerg
pathogen
daoust
et
al
fundament
differ
plant
address
manipul
secretori
pathway
glycoengin
coexpress
variou
protein
modifi
host
cell
environ
goulet
et
al
jutra
et
al
steinkelln
castilho
whilst
mani
consider
discuss
review
import
product
viral
glycoprotein
plant
like
addit
bottleneck
still
remain
bottleneck
may
even
vari
differ
viral
glycoprotein
factor
identifi
appropri
strategi
conceiv
expand
rang
viral
glycoprotein
produc
planta
conclus
use
molecular
farm
product
viral
glycoprotein
excit
rapidli
grow
applic
technolog
potenti
provid
urgent
need
vaccin
diagnost
region
need
